Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

InSightec Granted CFDA Approval for Fibroid Treatment Device

publication date: Jul 29, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
InSightec Ltd, an Israeli medical device maker, reported that its ExAblate System was approved for China marketing by the CFDA. ExAblate is a focused ultrasound device combined with continuous MRI imaging that is used to treat uterine fibroids non-invasively. GE Healthcare is majority owner of InSightec and contributed 90% of its $31 million C funding last year. More details....

Stock Symbol: (NYSE: GE)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors